206 related articles for article (PubMed ID: 29385562)
21. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
Burridge PW; Li YF; Matsa E; Wu H; Ong SG; Sharma A; Holmström A; Chang AC; Coronado MJ; Ebert AD; Knowles JW; Telli ML; Witteles RM; Blau HM; Bernstein D; Altman RB; Wu JC
Nat Med; 2016 May; 22(5):547-56. PubMed ID: 27089514
[TBL] [Abstract][Full Text] [Related]
22. RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin.
Reyes ME; Ma J; Grove ML; Ater JL; Morrison AC; Hildebrandt MAT
Toxicol Appl Pharmacol; 2018 Oct; 356():44-53. PubMed ID: 30031762
[TBL] [Abstract][Full Text] [Related]
23. Testosterone Antagonizes Doxorubicin-Induced Senescence of Cardiomyocytes.
Altieri P; Barisione C; Lazzarini E; Garuti A; Bezante GP; Canepa M; Spallarossa P; Tocchetti CG; Bollini S; Brunelli C; Ameri P
J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26746999
[TBL] [Abstract][Full Text] [Related]
24. Time course of changes in oxidative stress and stress-induced proteins in cardiomyocytes exposed to doxorubicin and prevention by vitamin C.
Ludke A; Akolkar G; Ayyappan P; Sharma AK; Singal PK
PLoS One; 2017; 12(7):e0179452. PubMed ID: 28678856
[TBL] [Abstract][Full Text] [Related]
25. The regulatory mechanisms of myogenin expression in doxorubicin-treated rat cardiomyocytes.
Liu ST; Huang SM; Ho CL; Yen LC; Huang CJ; Lin WS; Chan JY
Oncotarget; 2015 Nov; 6(35):37443-57. PubMed ID: 26452256
[TBL] [Abstract][Full Text] [Related]
26. LncRNA FOXC2-AS1 protects cardiomyocytes from doxorubicin-induced cardiotoxicity through activation of WNT1-inducible signaling pathway protein-1.
Zhang S; Yuan Y; Zhang Z; Guo J; Li J; Zhao K; Qin Y; Qiu C
Biosci Biotechnol Biochem; 2019 Apr; 83(4):653-658. PubMed ID: 30558506
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-29b Regulates the Mitochondria-Dependent Apoptotic Pathway by Targeting Bax in Doxorubicin Cardiotoxicity.
Jing X; Yang J; Jiang L; Chen J; Wang H
Cell Physiol Biochem; 2018; 48(2):692-704. PubMed ID: 30025410
[TBL] [Abstract][Full Text] [Related]
28. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes.
Zhao L; Zhang B
Sci Rep; 2017 Mar; 7():44735. PubMed ID: 28300219
[TBL] [Abstract][Full Text] [Related]
30. Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling.
Verheijen M; Schrooders Y; Gmuender H; Nudischer R; Clayton O; Hynes J; Niederer S; Cordes H; Kuepfer L; Kleinjans J; Caiment F
Toxicol Lett; 2018 Sep; 294():184-192. PubMed ID: 29803840
[TBL] [Abstract][Full Text] [Related]
31. Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Ellis JK; Wagh V; Nemade H; Hescheler J; Keun HC; Sachinidis A
Amino Acids; 2017 Dec; 49(12):1955-1963. PubMed ID: 28421296
[TBL] [Abstract][Full Text] [Related]
32. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
[TBL] [Abstract][Full Text] [Related]
33. Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells.
Madonna R; Cadeddu C; Deidda M; Spallarossa P; Zito C; Mercuro G
Curr Drug Targets; 2017; 18(6):719-723. PubMed ID: 27033187
[TBL] [Abstract][Full Text] [Related]
34. Assessment of herb-drug synergy to combat doxorubicin induced cardiotoxicity.
Jain A; Rani V
Life Sci; 2018 Jul; 205():97-106. PubMed ID: 29752960
[TBL] [Abstract][Full Text] [Related]
35. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
Ghigo A; Li M; Hirsch E
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
[TBL] [Abstract][Full Text] [Related]
36. Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death.
Chiosi E; Spina A; Sorrentino A; Romano M; Sorvillo L; Senatore G; D'Auria R; Abbruzzese A; Caraglia M; Naviglio S; Illiano G
J Interferon Cytokine Res; 2007 Jul; 27(7):589-97. PubMed ID: 17651020
[TBL] [Abstract][Full Text] [Related]
37. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.
Spallarossa P; Garibaldi S; Altieri P; Fabbi P; Manca V; Nasti S; Rossettin P; Ghigliotti G; Ballestrero A; Patrone F; Barsotti A; Brunelli C
J Mol Cell Cardiol; 2004 Oct; 37(4):837-46. PubMed ID: 15380674
[TBL] [Abstract][Full Text] [Related]
38. Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.
Vaidya TR; Mody H; Franco YL; Brown A; Ait-Oudhia S
AAPS J; 2021 Jan; 23(1):18. PubMed ID: 33404976
[TBL] [Abstract][Full Text] [Related]
39. Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis.
Fu P; Arcasoy MO
Biochem Biophys Res Commun; 2007 Mar; 354(2):372-8. PubMed ID: 17250809
[TBL] [Abstract][Full Text] [Related]
40. Redox-proteomic analysis of doxorubicin-induced altered thiol activity in cardiomyocytes.
Lin ST; Chou HC; Chen YW; Chan HL
Mol Biosyst; 2013 Mar; 9(3):447-56. PubMed ID: 23340498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
